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Abstract
We have previously reported that Ildr2 knockdown via adenovirally-delivered shRNA causes
hepatic steatosis in mice. In the present study we investigated hepatic biochemical and ana-
tomic phenotypes of Cre-mediated Ildr2 knock-out mice. Liver-specific Ildr2 knock-out mice
were generated in C57BL/6J mice segregating for a floxed (exon 1) allele of Ildr2, using con-
genital and acute (10-13-week-old male mice) Cre expression. In addition, Ildr2 shRNA was
administered to Ildr2 knock-out mice to test the effects of Ildr2 shRNA, per se, in the
absence of Ildr2 expression. RNA sequencing was performed on livers of these knockdown
and knockout mice. Congenital and acute liver-specific and hepatocyte-specific knockout
mice did not develop hepatic steatosis. However, administration of Ildr2 shRNA to Ildr2
knock-out mice did cause hepatic steatosis, indicating that the Ildr2 shRNA had apparent
“off-target” effects on gene(s) other than Ildr2. RNA sequencing and BLAST sequence align-
ment revealed Dgka as a candidate gene mediating these “off-target” effects. Ildr2 shRNA is
63% homologous to the Dgka gene, and Dgka expression decreased only in mice displaying
hepatic steatosis. Dgka encodes diacylglycerol kinase (DGK) alpha, one of a family of
DGKs which convert diacylglycerides to phosphatidic acid for second messenger signaling.
Dgka knockdown mice would be expected to accumulate diacylglyceride, contributing to the
observed hepatic steatosis. We conclude that ILDR2 plays a negligible role in hepatic stea-
tosis. Rather, hepatic steatosis observed previously in Ildr2 knockdown mice was likely due
to shRNA targeting of Dgka and/or other “off-target” genes. We propose that the gene candi-
dates identified in this follow-up study may lead to identification of novel regulators of hepatic
lipid metabolism.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the leading cause of liver failure
and transplantation in the United States and is predicted to affect ~30% of adults in the US [1].
Often considered the major liver manifestation of the metabolic syndrome, NAFLD is closely
associated with obesity, diabetes and insulin resistance [1, 2]. While the simple steatosis that
defines NAFLD is relatively benign, it can progress to non-alcoholic steatohepatitis (known as
NASH) with inflammatory infiltration and fibrosis [3]. The physiologic and metabolic factors
that cause NAFLD and trigger its progression to NASH remain poorly understood.
Recently, we described immunoglobulin-like domain containing receptor 2 (ILDR2) as a
novel modulator of NAFLD development [4]. Initially identified by positional genetics as a
diabetes-susceptibility gene in mice [5], Ildr2 knockdown via adenovirally-delivered shRNA
(ADKD) resulted in gross hepatic steatosis and inflammation within 10 days of infection [4].
Transcript analyses indicated initial increase in expression of genes mediating lipogenesis (3
days post-adenovirus infection), followed by decrease in expression of these transcripts after
development of steatosis, and differential expression of genes involved in the unfolded protein
response (ER stress) pathways [4].
In this previous study, we used an adenoviral delivery system to target hepatic short hairpin
RNA (shRNA) in order to produce an acute liver-specific knockdown of Ildr2 [4]. In the
absence (at the time) of any congenital Ildr2 KO mouse models, the Adv-shRNA system
allowed us to investigate the effects of acute knockdown of Ildr2 transcripts in the liver. How-
ever this system has effects beyond the knockdown of the target gene that confound interpreta-
tion: Adv infection is known to trigger hepatic inflammation [6–8] which plays a role in the
progression of NAFLD and development of NASH [9, 10]; Adv can also target other tissues,
and even though the majority is taken up by the liver [11–13], there are potential consequences
for gene expression in those tissues; and, finally, shRNA itself can have “off-target” effects and
reduce expression of genes not intentionally targeted [14, 15].
Here we describe liver-specific Ildr2 gene deletion models achieved using the Cre-loxP
system. We discuss the development of liver-specific Ildr2 knockout (KO) mice and fur-
ther characterize them to understand the putative role of Ildr2 in hepatic steatosis. The dif-
fering phenotypes observed in Ildr2 Adv-shRNA KD vs. KO models highlight some of the
pitfalls of using adenoviruses and shRNA for genetic manipulations; these are discussed
below.
Results
Congenital, hepatocyte-specific Ildr2 KO mice do not develop hepatic
steatosis
We introduced loxP sites flanking exon 1 of the Ildr2 gene (exon 1 is included in all seven
known Ildr2 transcript isoforms [5]) to create an Ildr2 floxed mouse (Ildr2fl/fl) (Fig 1A). To
explore the function of ILDR2 in the liver, we crossed Ildr2fl/flmice with mice expressing Cre
recombinase driven by the albumin promoter, obtaining hepatocyte-specific, congenital Ildr2
knockout mice (see Table 1 for nomenclature). Ildr2 liver mRNA expression was reduced
>99% in hepatocyte-specific Ildr2 KO mice (Ildr2Alb KO) compared to Ildr2fl/fl littermate con-
trols (Fig 1B and 1C). Although a subset of these mice retained Ildr2 expression–indicating
that the albumin-cre was not completely penetrant–these mice displayed no phenotypic differ-
ences vs. complete Ildr2Alb KO mice.
When fed, ad libitum, low-fat (9% kcal as fat) chow diet, male, Ildr2Alb KO mice did not dif-
fer in body weight or body composition from Ildr2fl/fl littermates (Fig 1D–1F). When fed ad
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Fig 1. Albumin-cre, Ildr2 KO mice do not develop hepatic steatosis. (A) Schematic of the floxed Ildr2 allele (not to scale). (B,C) Expression
of Ildr2, isoforms 1 and 4 in livers of 23-week old Ildr2Alb KO mice and littermate Ildr2fl/fl controls, fed chow or HFD for 17 weeks. Expression
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libitum a high-fat diet (HFD, 60% kcal as fat) from 6–23 weeks of age, they increased body
weight and fat mass in tandem with their Ildr2fl/flHFD-fed littermates (Fig 1D–1F).
23-week-old, chow-fed Ildr2Alb KO mice did not exhibit hepatic steatosis by inspection, his-
tology, or quantitative chemical analysis (Fig 1G–1K). They also had normal plasma triglycer-
ide and total cholesterol concentrations (Fig 1L and 1M). 23-week-old, HFD-fed mice showed
hepatic lipid accumulation and elevated plasma lipids, but there was no significant difference
between Ildr2Alb KO mice and littermate controls fed the same HFD (Fig 1G–1M).
Acute, hepatocyte-specific Ildr2 KO mice do not develop hepatic steatosis
The absence of steatosis in Ildr2Alb KO mice led us to postulate that the congenital nature of
the KO may have triggered gene compensation for the lack of ILDR2 during development.
The mouse albumin gene is turned on at ~E10.5, about halfway through embryonic develop-
ment [16], and Cre expression has been detected in fetal mouse hepatocytes from albumin-cre
mice as early as E14.5, as immature cells begin to differentiate into hepatocytes [17]. Critical
genes deleted at this stage in development may be compensated by functionally similar genes
[18–20]. Compensation for the loss of Ildr2 in Ildr2Alb KO mice could theoretically explain the
absence of increased steatosis in the Ildr2Alb KO mice.
To address this possibility, we designed a mouse model in which Ildr2 could be acutely
ablated in the adult animals, similar to the original Adv-shRNA KD mice (ADKD) mice. We
utilized an adeno-associated virus (AAV) construct incorporating thyroxine-binding globulin
(TBG) promoter-driven Cre or GFP (control). This AAV8-TBG-Cre (developed by the Penn
Vector Core) enables acute Cre expression specifically in hepatocytes [21, 22], knocking out
Ildr2 (Ildr2AAV KO). We injected AAV8-TBG-Cre intravenously into 13-week-old, chow-fed
Ildr2fl/flmice and examined livers 10 days post-injection, in keeping with the timeline of devel-
opment of steatosis in ADKD mice [4]. Despite complete KO of Ildr2 (Fig 2A and 2B), livers
of Ildr2AAV KO mice were normal, showing neither steatosis nor any lipid metabolic abnor-
malities when compared to mice injected with the AAV8-TBG-GFP control construct (Fig
2C–2F).
was measured by qPCR and normalized to 36b4, actb and Gapdh expression. (D) Body weight curves of HFD and chow-fed, Ildr2Alb KO
mice. (E,F) Percent fat mass and lean mass of HFD and chow-fed, Ildr2Alb KO mice measured weekly by NMR. (G) Photographs of livers
excised from HFD and chow-fed, Ildr2Alb KO mice at 23 weeks of age. (H) Hematoxylin and eosin staining of representative liver sections at
50X magnification. (I) Liver weight at 23 weeks of age. (J,K) Liver triglyceride and total cholesterol content (measured in duplicate). (L,M)
Plasma triglyceride and total cholesterol concentration at 23 weeks of age after a 4hr. fast. n = 4–5 mice per group. Data are represented as
mean ± standard error (SEM)  p<0.05,  p<0.01,  p<0.001 for Ildr2Alb KO vs. Ildr2fl/fl control. + p<0.05, ++ p<0.01, +++ p<0.001 for
chow vs. HFD.
https://doi.org/10.1371/journal.pone.0197548.g001
Table 1. Mouse models—nomenclature and abbreviations.















Ildr2fl/fl; albumin-cre Ildr2Alb KO Hepatocytes E14.5 (upon albumin
expression)











Ildr2fl/fl; adenoviral-cre Ildr2Adv KO All liver cells Adult; acute Ildr2fl/fl; Adv-GFP No difference from
control
https://doi.org/10.1371/journal.pone.0197548.t001
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Fig 2. AAV Ildr2 KO mice do not develop hepatic steatosis. (A,B) qPCR expression of Ildr2, isoforms 1 and 4 in livers of 13-week old mice, 10
days after i.v. injection with AAV-TBG-Cre (Ildr2AAV KO) or AAV-TBG-GFP (Ildr2fl/fl controls). (C,D) Liver triglyceride and total cholesterol
ILDR2 has a negligible role in hepatic steatosis
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To determine the timing of AAV delivery and gene interruption, we measured hepatic
mRNA expression of Ildr2 isoforms 1 through 5 (only isoform 1 is shown) in mice at 2, 4, 6, 8,
10 and 12 days post injection and found that Ildr2 transcription was eliminated as early as 2
days post-injection (Fig 2G). We also followed mice for 6 weeks after AAV infection, measur-
ing plasma lipids at 20 days post-injection, and then at 11-day intervals until sacrifice. Ildr2AAV
KO mice maintained normal plasma lipid levels and did not exhibit any hepatic lipid accumu-
lation or metabolic abnormalities at 6 weeks post-injection with AAV (Fig 2H–2L).
Acute, Adv-mediated, liver-specific Ildr2 KO mice do not develop hepatic
steatosis
Next, we considered the possibility that loss of Ildr2 in non-parenchymal liver cells may have
contributed significantly to the steatosis observed in our original ADKD mice [4]. Both the
AAV-TBG-Cre and the albumin-cre were designed to induce recombination and gene knock-
out specifically in hepatocytes which comprise ~80% of liver tissue. However, the shRNA ade-
novirus used to produce ADKD mice would have targeted additional liver cell types, such as
liver macrophages (Kupffer cells), stellate cells, and epithelial cells. While hepatic steatosis is
defined by lipid accumulation in hepatocytes, effects in non-parenchymal liver cells can accel-
erate the progression of steatosis to more advanced liver disease [23–26]. As resident liver mac-
rophages, Kupffer cells initiate the immune response to metabolic injury, secreting pro-
inflammatory chemokines and cytokines such as IL-1β and TNF, stimulating pro-apoptotic
signaling pathways in hepatocytes, and recruiting circulating immune cells to the liver [26–
28]. Stellate cells play a key role in the induction of fibrosis in liver disease, and can transdiffer-
entiate into myofibroblasts leading to increased production of collagen and extra-cellular
matrix (ECM) [25, 28, 29].
To determine if Ildr2 is expressed in non-parenchymal liver cells, or in hepatocytes only,
primary hepatocytes and non-parenchymal cells were isolated from 12-week-old mice using
liver collagenase digestion [4]. Hepatocyte and non-hepatocyte cell fractions were separated by
centrifugation [30]. Gene expression analysis of liver cell markers was used to confirm the cel-
lular identity of each fraction. Tbg, a hepatocyte-specific marker, and F4/80, a macrophage-
specific marker, were highly expressed in the hepatocyte and non-hepatocyte fractions, respec-
tively (Fig 3B and 3C). Ildr2 was expressed in both cell fractions, although at about one-third
the level in the non-hepatocyte cell fraction as in the hepatocyte cell fraction (Fig 3A). How-
ever, since these cell fractions were sorted by centrifugation there could be cross-contamina-
tion as indicated by low-level Tbg expression in the non-hepatocyte fraction, and F4/80
expression in hepatocyte fraction (Fig 3B and 3C). Microarray expression data from Xu, et al.
also confirm that Ildr2 is expressed in various populations of macrophages derived from adi-
pose tissue [31]. Taken together, these results suggest that Ildr2 ablation in non-parenchymal
liver cells could contribute to the steatotic phenotypes of the ADKD mice, and thus explain the
lack of hepatic steatosis in the acute and congenital transgenic hepatocyte-specific KO mice.
To test this possibility, we created another acute Ildr2 KO model by using an adenoviral-
Cre construct rather than the AAV-TBG-Cre used previously. While the AAV-TBG-Cre con-
struct is designed to impact only hepatocytes, adenoviral-Cre targets both parenchymal and
content at 10 days. (E,F) Plasma triglyceride and total cholesterol concentration at 10 days. (G) qPCR expression of Ildr2 (isoform 1 unless
otherwise noted) in livers of 13-week old mice 2–12 days after i.v. injection with AAV-TBG-Cre (Ildr2AAV KO). AAV-TBG-GFP was only
administered for the 2-day timepoint (Ildr2fl/fl controls). (H) qPCR expression of Ildr2 in livers of 18-week old mice, 6 weeks after AAV injection
(I,J) Liver triglyceride and total cholesterol measurements. (K,L) Plasma triglyceride and total cholesterol concentration at 20, 31 and 42 days
after AAV injection. Blood was collected after a 4hr fast. n = 4–5 mice per group.  p<0.05,  p<0.01,  p<0.001 for Ildr2AAV KO vs. Ildr2fl/fl
control.
https://doi.org/10.1371/journal.pone.0197548.g002
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Fig 3. Adenoviral Ildr2 KO mice do not develop hepatic steatosis. (A-C) qPCR expression of Ildr2, Tbg and F4/80 in hepatocyte or non-parenchymal cell
fractions isolated from 12-week old wild-type (B6) mice. (D) qPCR expression of Ildr2 in livers of 11-week old mice, 10 days after i.v. injection with adenoviral-
Cre (Ildr2Adv KO), adenoviral-GFP (Ildr2fl/fl controls), AAV-TBG-Cre (Ildr2AAV KO) or AAV-TBG-GFP (Ildr2fl/fl controls). (E) Liver weights at sac. (F-H) Liver
triglyceride, total cholesterol and glycogen content. (I,J) Plasma triglyceride and total cholesterol concentration at sac following a 12hr fast. (K) Hematoxylin and
eosin staining of representative liver sections at 20X magnification. n = 4–5 mice per group.  p<0.05,  p<0.01,  p<0.001 for Ildr2 KO vs. Ildr2fl/fl control. +
p<0.05, ++ p<0.01, +++ p<0.001 for adenovirus vs. AAV.
https://doi.org/10.1371/journal.pone.0197548.g003
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non-parenchymal liver cells [32, 33]. 11-week-old, male, Ildr2fl/flmice were injected intrave-
nously with adenovirus-Cre or adenovirus-GFP as a control. Age-matched Ildr2fl/flmice were
infected with AAV-TBG-Cre or AAV-TBG-GFP at the same time for parallel comparison.
Ildr2Adv KO mice were euthanized 10 days post-injection. No liver steatosis or dyslipidemia
were seen in Ildr2Adv or Ildr2AAV KO mice despite complete Ildr2 ablation in liver (Fig 3D and
3F–3J). Ildr2Adv KO livers were heavier compared to Ildr2AAV KO mice (Fig 3E), and also
showed histological evidence of inflammation (Fig 3K). However, as these phenotypes were
also present in the Ildr2Adv GFP control mice, we attributed them to the effects of adenovirus
treatment as has been documented previously [6–8].
Administration of adenoviral Ildr2 shRNA causes TG accumulation in
Ildr2Alb KO mice
We have produced three distinct models of hepatic Ildr2 KO: a congenital, hepatocyte-specific
KO (Ildr2Alb KO); an acute, hepatocyte-specific, KO (Ildr2AAV KO); and an acute, liver-specific
KO (Ildr2Adv KO). None of these models showed the severe steatohepatitis observed in the ade-
noviral Ildr2 shRNA (ADKD) model [4]. Thus, we were driven to consider that the steatosis
had been caused by a consequence of the shRNA antisense construct–primarily unrelated to
the decrease in Ildr2 expression.
The original ADKD model was produced by treating mice with an adenovirally-delivered
shRNA. Thus, the adenovirus treatment and/or the shRNA itself may have triggered liver stea-
tosis. Since we showed that adenoviral treatment alone does not cause hepatic steatosis, so we
turned our attention to the Ildr2 shRNA. This shRNA was specifically designed to target exon
2 which is present in all isoforms of Ildr2 mRNA; however, the construct may have had “off
target” effects on other genes as discussed below [14, 15, 34].
To determine if other targets of the shRNA contributed to the KD liver phenotype, we
infected Ildr2Alb KO mice with the original KD adenoviral shRNA [4]. Since these mice do not
express Ildr2 in the hepatocytes, any steatosis observed would be the result of shRNA targeting
of other genes affecting lipid metabolism. 10-week-old, male, Ildr2Alb KO or Ildr2flfl control
mice were injected intravenously with the original adenovirus expressing Ildr2 shRNA
(ADKD), or with control adenovirus expressing lacZ shRNA (AD-lacZ) [4]. Mice were eutha-
nized at 10 days post-adenovirus infection following a 24-hour fast. Gene expression analysis
by qPCR confirmed that Ildr2 was completely ablated in Ildr2Alb KO mice, regardless of Adv
treatment (Fig 4A). In Ildr2flfl mice, Ildr2 shRNA (ADKD) reduced Ildr2 mRNA by about 50%
vs. AD-lacZ treated Ildr2flfl mice (Fig 4A). We did not observe gross liver steatosis, but chemi-
cal quantification of hepatic lipid content revealed that ADKD-treated mice had significantly
increased hepatic TG compared to AD-lacZ treated mice, across both genotypes (3-fold in
Ildr2flfl, 1.5-fold in Ildr2Alb KO) (Fig 4B and 4C). Conversely, plasma TG was significantly
decreased in Ildr2 shRNA treated Ildr2Alb KO and Ildr2flfl mice vs. AD-lacZ treated mice for
both genotypes, although plasma cholesterol was unchanged (Fig 4D and 4E).
These results confirm that the Ildr2 shRNA is sufficient to cause hepatic steatosis despite
the preexisting absence of Ildr2. Ildr2 expression was reduced by 50% in Ildr2 shRNA Ildr2flfl
mice, indicating that acute partial loss of Ildr2 expression might contribute to the development
of steatosis. However, the degree of steatosis and hypotriglyceridemia did not differ between
Ildr2 shRNA Ildr2flfl and Ildr2 shRNA Ildr2Alb KO mice, suggesting that Ildr2 expression is
either irrelevant to the phenotype or has an equivalent effect at levels below a specific thresh-
old, i.e. below 50%. In either case, the major trigger for hepatic steatosis is the Ildr2 shRNA,
not Ildr2 ablation per se.
ILDR2 has a negligible role in hepatic steatosis
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These results suggest that the Ildr2 shRNA also targets other gene(s) involved in hepatic
lipid metabolism, and that KD of these gene(s) is primarily responsible for the gross steatosis
in the original Ildr2 shRNA ADKD mice [4] as well as the less striking, but still significantly
increased TG accumulation observed here.
RNAseq analysis of Ildr2 shRNA ADKD vs. Ildr2Adv KO livers reveal
candidate genes for shRNA off-target effects on hepatic steatosis
The Ildr2 shRNA we used was designed to target exon 2 of the Ildr2 mRNA, which is present
in all known Ildr2 isoforms. Analysis of the 19 base pair (bp) shRNA sequence, GTTCAAAT
CCTACTGCCAG, using NCBI BLAST (Basic Sequence Alignment Search Tool) identified no
perfectly matched sequences (other than Ildr2) leaving open the possibility that partially
matched sequence(s) could be targeted and cause knockdown of gene(s) essential for hepatic
lipid homeostasis [15, 34].
To identify additional gene(s) that might have been knocked down by the Ildr2 shRNA, and
thus have contributed to development of steatosis in ADKD mice, we performed RNA
sequencing analysis on liver samples from ADKD and AD-lacZ mice (from our previously
published ADKD study [4]) and Ildr2Adv KO mice (Fig 3). ADKD and AD-lacZ samples were
harvested 3 days post Adv infection to increase the likelihood of detection of primary effects of
knocking down the gene rather than secondary gene changes resulting from hepatic steatosis
per se.
Fig 4. Effects of adenoviral Ildr2 shRNA in Ildr2 KO mice. (A) qPCR expression of Ildr2 in livers of 10-week old mice Ildr2Alb KO mice and littermate
Ildr2fl/fl controls, 10 days after i.v. injection with ADKD or AD-lacZ. (B,C) Liver triglyceride and total cholesterol content. (D-E) Plasma triglyceride and
total cholesterol concentration at sac following a 24hr fast. n = 5–6 mice per group.  p<0.05,  p<0.01,  p<0.001 for Ildr2fl/fl vs. Ildr2Alb KO; & p<0.05
for ADKD vs. AD-lacZ.
https://doi.org/10.1371/journal.pone.0197548.g004
ILDR2 has a negligible role in hepatic steatosis
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RNAseq count expression data were analyzed with DEseq, a differential expression analysis
program based on the negative binomial distribution [35]. Pairwise comparisons were made
between Ildr2 shRNA (ADKD) and AD-lacZ; Ildr2 shRNA ADKD and Ildr2Adv KO; and AD-
lacZ and Ildr2Adv KO. The Benjamini-Hochberg adjustment [36] was used to correct for the
multiple testing problem. Fig 5A–5C are “minus over average” (MA) scatter plots of differen-
tial gene expression profiles for each of the 3 comparisons. MA plots display the entire gene
set, comparing fold change between samples (y-axis) to mean expression value (x-axis) with
significantly differentially expressed genes highlighted in red (Fig 5A–5C). We screened for
candidate genes that were: 1) significantly decreased in ADKD vs. AD-lacZ; 2) significantly
decreased in ADKD vs. Ildr2Adv KO; and, 3) not significantly changed between AD-lacZ and
Ildr2Adv KO livers, indicating a specific effect of the KD Ildr2 shRNA shRNA (Fig 5D). Using
these parameters, we identified 102 candidate genes (S1 Table).
These candidates were further refined by searching for genes that have been implicated in
NAFLD genome-wide association studies (Ppp1ca) [38], genes associated with other liver dis-
ease, (Dguok, Ass1) [39, 40], and obesity-related genes (Slc39a1) [41]. Since the shRNA was tar-
geted to Ildr2’s exon 2 which encodes for an IgG domain, we identified genes that are part of
the IgG-like family (Neo1, Ptp4a1, Scn8a, Unc13b); additionally, we found a gene located near
Ildr2 on chromosome 1 (Pogk) [5].
Fig 5. RNAseq analysis of AdV-KD vs. Ildr2Adv KO livers identifies candidate genes for shRNA off-target effects. “Minus over
average” (MA) plots showing log2 fold change vs. normalized mean for each comparison. Red dots represent significantly upregulated
or downregulated genes in (A) ADKD vs. AD-lacZ mice, (B) ADKD and Ildr2Adv KO mice, (C) AD-lacZ vs. Ildr2Adv KO mice. (D)
Venn diagram illustrating how the 102 candidate genes were identified. The intersection of genes downregulated in ADKD mice vs.
both AD-lacZ and Ildr2Adv KO was 204. 102 of these genes were not significantly changed in AD-lacZ vs. Ildr2Adv KO. These became
the target gene candidates (see S1 Table for complete list). This Venn diagram was created using BioVenn software [37] (www.
biovenn.nl).
https://doi.org/10.1371/journal.pone.0197548.g005
ILDR2 has a negligible role in hepatic steatosis
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Initial BLAST searches of the shRNA sequence yielded no complete match apart from Ildr2.
However, searching for truncated portions of the 19-bp sequence yielded a partial match in
Dgka. Dgka is one of the 102 candidate genes identified by RNAseq analysis (S1 Table), and is
63% homologous to the Ildr2 shRNA sequence. The first 12 bp of the 19 bp shRNA sequence,
GTTCAAATCCTA, exactly a sequence in exon 4 of the Dgka mRNA. Dgka expression is down-
regulated by 50–60% in ADKD livers compared to AD-lacZ and Ildr2Adv KO samples, suggest-
ing that it could be targeted by the Ildr2 shRNA. Dgka encodes diacylglycerol kinase alpha
(DGKα), which functions to convert diacylglycerides (DAGs) to phosphatidic acid [42]. DAG
species are increased in mouse embryonic fibroblasts from Dgka-null mice [43] similar to
increases in DAG species observed in steatotic human liver [44]. These data suggest that loss of
Dgka expression could result in the steatosis observed in our ADKD mice.
Discussion
In this study we describe several mouse models developed in an effort to replicate the hepatic
steatosis phenotype of adenoviral Ildr2 shRNA KD mice. Using the Cre-loxP system, we cre-
ated congenital and acute, hepatocyte-only and liver-specific Ildr2 KO mice. However, none of
these KO models recapitulated the phenotype of hepatic steatosis observed in the adenoviral
Ildr2 shRNA KD mice [4].
RNAi-mediated knockdowns have been effectively used in many experimental settings, and
are particularly useful in in vitro studies, and in instances in which a genetic knockout would
be prohibitively expensive or difficult to make, or where the knockout is embryonically lethal.
KD and KO models are generally quite similar, e.g., Pparα siRNA KD mice phenocopy the
null transgenics [45] and Cx43 KO and KD mouse astrocytes have very similar transcriptional
profiles [46].
However, discrepancies between RNAi-mediated KD and KO mouse models are not
uncommon. As observed in this study and by others, siRNAs and shRNAs can have off-target
effects due to sequence similarity to unintended gene targets [14, 15, 34]. RNAi-mediated
knockdowns can also exhibit a more severe phenotype than the KO or null mutant due to dis-
ruption of the gene at a more mature developmental stage, when functional compensation is
difficult [18, 47]. This situation has been documented, for example, for the genes thymosin β4
and Sprn/Prnp in mice, and ABP1 in Arabdopsis thaliana [48–50].
Our studies in which Ildr2 shRNA KD adenovirus was administered to Ildr2Alb KO mice
revealed that lipid accumulation occurred with the adenovirus treatment, regardless of Ildr2
genotype of the recipient mouse (Fig 4). These experiments indicate that the hepatic lipid phe-
notype is due primarily to treatment with the adenovirus shRNA, rather than to loss of Ildr2
expression per se, which suggests that this shRNA targeted genes in addition to Ildr2. We iden-
tified Dgka, among other gene candidates, as a potential target of adenoviral Ildr2 shRNA in
ADKD mice. Given its homology to the shRNA sequence, its reduced expression in ADKD
mice, and its functional role in lipid metabolism [43, 44, 51], we propose that shRNA targeting
of Dgka could account for the difference in lipid accumulation between ADKD and KO mice.
Adenovirus is an efficient vector for introduction of gene products into cells both in vitro
and in vivo. The adenovirus used in this and our previous study [4] was human adenovirus
serotype 5, one of the most commonly used adenoviruses which displays specific liver tropism,
and thus is very useful for directing gene products to the liver. However, use of adenoviruses
in these contexts can be problematic for several reasons. One overriding concern is that, since
they are infectious agents, they can stimulate inflammatory responses in the infected cells [6–
8]. This response can mask or confound the effect(s) of whatever biological molecules are
being delivered to the cells. Another issue with adenovirus is that its tissue tropism, while
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specific, is not exclusive, and it can affect tissues other than the target tissue [11]. Additionally,
the various methods of measuring adenoviral titer make it difficult to control the amount of
active virus that is administered in an experiment, which can lead to significant variation
among experiments. The sensitivity of viral activity to temperature changes, i.e. freeze-thaw
cycles, also contributes to experimental variability [52, 53].
The experiments described here highlight some of the difficulties in working with adenovi-
ruses. In addition to possible aberrant RNAi gene targeting, the striking phenotype of the orig-
inal ADKD mice may also have been due to adenovirus-induced inflammation and /or
targeting of extra-hepatic tissues. While we confirmed that Ildr2 expression was maintained in
other tissues of ADKD mice [4], we cannot rule out that the Adv may have infected other
organs. Another concern is that the amount of active Ildr2 shRNA adenovirus used to infect
Ildr2Alb KO mice may have decreased from its activity level at the time of ADKD infection.
Although the same titer was used in both experiments (3x1011 optical particle units (OPU)/
mouse), this titer only measures adenovirus concentration, not viral activity. A reduction in
adenoviral activity could also explain the difference in lipid accumulation and severity of stea-
tosis between ADKD mice and Ildr2Alb KO mice infected with Adv-Ildr2 shRNA. Use of
appropriate controls enabled us to deconvolute the effects of Ildr2 expression on hepatic stea-
tosis in our various mouse models; however, the confounding effects of using adenovirus as a
primary delivery system remain a significant issue.
Conclusions
We have clearly shown that loss of Ildr2—whether specifically in hepatocytes or in all liver cells—
is not sufficient to cause hepatic steatosis. These studies indicate that, contrary to the inferences
reached based on acute shRNA-mediated KD [4], ILDR2 plays a minimal role in hepatic lipid
metabolism. We propose that interruption of other gene(s) significantly contributed to the steato-
tic phenotype of the original ADKD. RNA-seq identified 102 genes that are significantly reduced
in ADKD mice vs. Ildr2Adv KOs or AD-lacZ controls (S1 Table). Among these 102 genes, the
most likely candidate is Dgka, which contains a sequence that could be targeted by the Ildr2
shRNA. It is worth noting that hepatic lipid accumulation due to Adv-Ildr2 shRNA treatment was
only observed in mice with at least a 50% reduction in Ildr2 expression. Thus, it is possible that
KD of candidate gene(s) interacts with Ildr2 hypomorphism to induce steatosis.
Ildr2 was initially identified as modifier of diabetes susceptibility [5], and ongoing work in
our lab has confirmed its role in beta cell function, glucose homeostasis, and metabolic parti-
tioning of energy stores. Additionally, ILDR2, along with ILDR1 and ILDR3, are members of
the angulin family which maintain membrane integrity at tricellular epithelial tight junctions
[54, 55]. Our development of conditional KO mice to clarify the role of ILDR2 in the liver, can
now facilitate the study of ILDR2 in various tissues and conditions, enabling a more complete
understanding of this novel gene in mammalian biology.
Methods
Ethics statement
All animal experiments were approved by Columbia Institutional Animal Care and Use Com-
mittee (Protocol# AAAH0707 and AAAR0416).
Animal care
Mice were housed at room temperature in a 12-hr light/12hr-dark vivarium, with ad libitum
access to 5058 Purina PicoLab Mouse Diet 20 (9% kcal from fat) and water. High-fat diet
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(HFD) fed mice received chow with 60% kcal from fat (Research Diets #D12492i). Where
noted, blood was collected by submandibular bleeding. Fat and lean mass were measured with
an EchoMRI Analyzer (Bruker Optics), calibrated using mouse carcasses [56]. Mice were
euthanized by cervical dislocation for liver tissue collection or prior to primary hepatocyte
isolation.
Mouse strains
To generate Ildr2 floxed mice (Ildr2fl/fl), a targeting construct containing Ildr2 exon 1 flanked
by loxP sites and a neomycin resistance cassette (transcribed in opposite direction of gene, 1.6
kb from exon 1) was electroporated into V6.5 (129 x B6 F1) ESCs. Electroporated ESCs were
selected with G418, picked, and 384 colonies were clonally expanded. Positive integration of
the targeting construct was identified by PCR followed by confirmation of correct integration
by Southern blot. A positive clone was injected into E3.5 BDF1 blastocytes and transferred
into the uteri of pseudopregnant CD1 mice (Crl:CD1; Charles River). Floxed alleles in the
pups were confirmed by PCR. Chimeric mice were crossed with C57BL/6J (Jackson Labs)
mice and offspring were confirmed carriers by PCR and Southern blot analysis. Mice that car-
ried the floxed allele were backcrossed to C57BL/6J mice (obtained from Jackson Labs) for 10
generations then intercrossed to create B6.129S-Ildr2fl/flmice. These mice were bred with albu-
min-Cre mice (B6.Cg-Tg(Alb-cre)21Mgn/J, Jackson Labs stock #003574) until all offspring
segregated for two floxed alleles and one or no copies of Cre.
Adenovirus production and administration
Adenovirus expressing Ildr2 shRNA was designed, produced and amplified as previously
described [4]. Adenovirus expressing lacZ shRNA was designed and produced as previously
described [4], but amplification and purification procedures were performed by Welgen, Inc
(Worcester, MA). Mice were administered 3x1011 OPU/mouse via tail vein injection.
AAV-TBG-Cre, AAV-TBG-eGFP, adenoviral-Cre, and adenoviral-GFP were obtained from
the University of Pennsylvania Vector Core (Philadelphia, PA). Mice were administered
1.3x1011 genome copies/mouse via tail vein injection.
Lipid measurements in tissue and plasma
Capillary blood from submandibular bleeds was collected in heparinized tubes and centrifuged
at 200 x g for 20 minutes at 4˚C to separate plasma. Lipid extraction from liver was adapted
from the Folch method [57]. Approximately 100 mg tissue were homogenized in 3 mL phos-
phate-buffered saline (PBS). 12 mL 2:1 chloroform: methanol (CHCl3: MeOH) were added
and mixture was vortexed twice for 15 seconds each. After centrifuging at 3000 rpm for 10
minutes, the organic lower layer was transferred to a 20-mL glass scintillation vial. An addi-
tional 10 mL 2:1 CHCl3: MeOH were added to upper layer and vortexing and centrifugation
were repeated. Organic lower layer was added to first extraction in scintillation vial. Solvent
was dried down under nitrogen (N2) gas followed by lipid resuspension in 1 mL 15% Triton
X-100 in CHCl3. Solvent was dried down again under N2 gas and remaining lipid was resus-
pended in 1mL H2O. Triglyceride and total cholesterol in plasma and liver extracts were mea-
sured with the Infinity Triglycerides (Thermo Scientific) and Cholesterol E (Wako
Diagnostics) kits, respectively.
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Glycogen measurement
For glycogen extraction 100 mg tissue were homogenized in 1 mL H2O on ice, boiled for 10
minutes, then centrifuged at 13,000 x g for 10 minutes to pellet insoluble material. Supernatant
was transferred to a new tube and used for glycogen measurement. Glycogen was measured
using a glycogen assay kit from Sigma-Aldrich (#MAK016)
Primary hepatocyte and non-parenchymal cell isolation
Primary hepatocytes isolation was performed as previously described [4] with the exception of
euthanasia prior to laparotomy and perfusion. The supernatant from primary hepatocyte cen-
trifugation was collected and spun down at 500 x g, for 10 minutes at 4˚C according to a proto-
col for isolating Kupffer cells by Xu, et al. [30]. The pelleted cells from this centrifugation were
considered the non-parenchymal cell fraction.
Hematoxylin and eosin histology
Liver sections were fixed in aqueous zinc-buffered formalin (Anatech, Ltd.), sectioned and
visualized by hematoxylin (Fisher) and eosin (Crystalgen) staining. Images were obtained
using an Olympus IX73 inverted microscope (Olympus America).
RNA extraction, reverse transcription and quantitative PCR
Tissue and cell samples were homogenized in TRIzol1 Reagent (Invitrogen) and extracted
using the TRIzol1 reagent protocol or the PureLink™ RNA Mini kit (Invitrogen). Reverse
transcription was performed using the Transcriptor First Strand cDNA Synthesis kit (Roche).
qPCR was performed using a Roche LightCycler1 480 instrument. qPCR primers are listed in
Table 2. Tissue-specific standard curves for each gene (primer pair) were used to convert
threshold crossing point (Cp) values to relative concentrations, which were then normalized to
36b4, Actb, and/or Gapdh expression. In instances in which standard curves were not used, Cp
values are shown, with lower Cp values indicating greater mRNA expression.
RNAseq
RNA was extracted from liver samples as detailed above and sample integrity was assessed
with an Agilent 2100 Bioanalyzer with all samples having RIN numbers greater than 8.0.
mRNA was isolated using a poly-A pulldown [58] and reverse transcription to generate
cDNA. The cDNA was sequenced using single-ended sequencing on a HiSeq2000 according
to manufacturer’s recommendations (Illumina; San Diego, CA). The pass filter (PF) reads
were mapped to mouse reference genome mm9 using TopHat (version 2.0.4). TopHat infers
novel exon-exon junctions ab initio, and combines them with junctions from known mRNA
Table 2. List of qPCR primers.




Ildr2 –isoform 1 GATTATGCCAGAGTGGGTGTTTGTC CCCTGCTTCATACAAGGCCTGAG
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sequences (refgenes) as the reference annotation [59]. For each read, we allowed up to 3 mis-
matches and 10 multiple hits during the mapping. The software package DESeq [35] in R (Ver-
sion 3.4.1) was used to conduct the differential gene expression analysis. Multiple comparisons
were adjusted by the Benjamini-Hochberg approach, and differentially expressed genes were
determined at false discovery rate of 0.01.
Statistical analysis
Statistics were performed using GraphPad Prism 7 software. Data are represented as
mean ± standard error (SEM). Statistical comparisons were made using the Student’s two-
tailed t-test for 2 groups or two-way analysis of variance (ANOVA) for 4 groups.
Supporting information
S1 Table. RNAseq candidate gene list.
(PDF)
Acknowledgments
The authors would like to thank the technical personnel in the Naomi Berrie Diabetes Center
histology core for their assistance and members of the Leibel lab for helpful advice and discus-
sion. We are especially grateful to Dr. Domenico Accili, Dr. Henry Ginsberg, Dr. Utpal Paj-
vani, and Dr. Ira Tabas for providing guidance at multiple stages of this project.
Author Contributions
Conceptualization: Elizabeth J. Millings, Maria Caterina De Rosa, Kazuhisa Watanabe,
Charles A. Leduc, Yiying Zhang, Stuart G. Fischer, Rudolph L. Leibel.
Data curation: Elizabeth J. Millings.
Formal analysis: Elizabeth J. Millings, Sarah Fleet, Gen Li, Charles A. Leduc.
Funding acquisition: Rudolph L. Leibel.
Investigation: Elizabeth J. Millings, Maria Caterina De Rosa, Sarah Fleet, Kazuhisa Watanabe,
Richard Rausch, Charles A. Leduc.
Methodology: Elizabeth J. Millings, Maria Caterina De Rosa, Kazuhisa Watanabe, Dieter Egli,
Charles A. Leduc, Yiying Zhang, Rudolph L. Leibel.
Project administration: Elizabeth J. Millings, Charles A. Leduc, Rudolph L. Leibel.
Resources: Kazuhisa Watanabe, Richard Rausch.
Software: Gen Li.
Supervision: Elizabeth J. Millings, Charles A. Leduc, Rudolph L. Leibel.
Validation: Elizabeth J. Millings, Charles A. Leduc.
Visualization: Elizabeth J. Millings, Gen Li, Stuart G. Fischer.
Writing – original draft: Elizabeth J. Millings, Charles A. Leduc, Stuart G. Fischer, Rudolph
L. Leibel.
Writing – review & editing: Elizabeth J. Millings, Kazuhisa Watanabe, Gen Li, Charles A.
Leduc, Yiying Zhang, Stuart G. Fischer, Rudolph L. Leibel.
ILDR2 has a negligible role in hepatic steatosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0197548 May 30, 2018 15 / 19
References
1. Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World Journal of Hepatol-
ogy. 2017; 9(16):715–32. https://doi.org/10.4254/wjh.v9.i16.715 PubMed PMID: PMC5468341. PMID:
28652891
2. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic
fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology.
2016; 64(1):73–84. https://doi.org/10.1002/hep.28431 PMID: 26707365
3. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology. 2006;
43(S1):S99–S112. https://doi.org/10.1002/hep.20973 PMID: 16447287
4. Watanabe K, Watson E, Cremona ML, Millings EJ, Lefkowitch JH, Fischer SG, et al. ILDR2: an endo-
plasmic reticulum resident molecule mediating hepatic lipid homeostasis. PLoS One. 2013; 8(6):
e67234. https://doi.org/10.1371/journal.pone.0067234 PMID: 23826244; PubMed Central PMCID:
PMC3691114.
5. Dokmanovic-Chouinard M, Chung WK, Chevre JC, Watson E, Yonan J, Wiegand B, et al. Positional
cloning of "Lisch-Like", a candidate modifier of susceptibility to type 2 diabetes in mice. PLoS genetics.
2008; 4(7):e1000137. https://doi.org/10.1371/journal.pgen.1000137 PMID: 18654634; PubMed Central
PMCID: PMC2464733.
6. Liu Q, Muruve DA. Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther.
2003; 10(11):935–40. https://doi.org/10.1038/sj.gt.3302036 PMID: 12756413
7. Muruve DA, Barnes MJ, Stillman IE, Libermann TA. Adenoviral Gene Therapy Leads to Rapid Induction
of Multiple Chemokines and Acute Neutrophil-Dependent Hepatic Injury in Vivo. Human Gene Therapy.
1999; 10(6):965–76. https://doi.org/10.1089/10430349950018364 PMID: 10223730
8. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG. Innate Immune Mechanisms Dominate Elimination
of Adenoviral Vectors Following In Vivo Administration. Human Gene Therapy. 1997; 8(1):37–44.
https://doi.org/10.1089/hum.1997.8.1-37 PMID: 8989993
9. Ganz M, Szabo G. Immune and inflammatory pathways in NASH. Hepatology International. 2013; 7
(2):771–81. https://doi.org/10.1007/s12072-013-9468-6 PMID: 24587847
10. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel
hits hypothesis. Hepatology. 2010; 52(5):1836–46. https://doi.org/10.1002/hep.24001 PMID: 21038418
11. Wood M, Perotte P, Onishi E, Harper ME, Dinney C, Pagliaro L, et al. Biodistribution of an adenoviral
vector carrying the luciferase reporter gene following intravesical or intravenous administration to a
mouse. Cancer Gene Therapy. 1999; 6(4):367–72. https://doi.org/10.1038/sj.cgt.7700090 PMID:
10419055
12. Beatty MS, Curiel DT. Adenovirus Strategies for Tissue-Specific Targeting. Advances in cancer
research. 2012; 115:39–67. https://doi.org/10.1016/B978-0-12-398342-8.00002-1 PubMed PMID:
PMC3664935. PMID: 23021241
13. Shayakhmetov DM, Li Z-Y, Ni S, Lieber A. Analysis of Adenovirus Sequestration in the Liver, Transduc-
tion of Hepatic Cells, and Innate Toxicity after Injection of Fiber-Modified Vectors. Journal of Virology.
2004; 78(10):5368–81. https://doi.org/10.1128/JVI.78.10.5368-5381.2004 PMID: 15113916
14. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, et al. Expression profiling reveals
off-target gene regulation by RNAi. Nat Biotech. 2003; 21(6):635–7. http://www.nature.com/nbt/journal/
v21/n6/suppinfo/nbt831_S1.html.
15. Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L, et al. Widespread siRNA “off-target”
transcript silencing mediated by seed region sequence complementarity. RNA. 2006; 12(7):1179–87.
https://doi.org/10.1261/rna.25706 PMID: 16682560
16. Meehan RR, Barlow DP, Hill RE, Hogan BL, Hastie ND. Pattern of serum protein gene expression in
mouse visceral yolk sac and foetal liver. The EMBO journal. 1984; 3(8):1881–5. PubMed PMID:
PMC557612. PMID: 6479150
17. Weisend CM, Kundert JA, Suvorova ES, Prigge JR, Schmidt EE. Cre activity in fetal albCre mouse
hepatocytes: Utility for developmental studies. genesis. 2009; 47(12):789–92. https://doi.org/10.1002/
dvg.20568 PMID: 19830819
18. Rossi A, Kontarakis Z, Gerri C, Nolte H, Holper S, Kruger M, et al. Genetic compensation induced by
deleterious mutations but not gene knockdowns. Nature. 2015; 524(7564):230–3. https://doi.org/10.
1038/nature14580 http://www.nature.com/nature/journal/v524/n7564/abs/nature14580.
html#supplementary-information. PMID: 26168398
19. Hagelkruys A, Lagger S, Krahmer J, Leopoldi A, Artaker M, Pusch O, et al. A single allele of Hdac2 but
not Hdac1 is sufficient for normal mouse brain development in the absence of its paralog. Development.
2014; 141(3):604–16. https://doi.org/10.1242/dev.100487 PMID: 24449838
ILDR2 has a negligible role in hepatic steatosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0197548 May 30, 2018 16 / 19
20. Deconinck AE, Rafael JA, Skinner JA, Brown SC, Potter AC, Metzinger L, et al. Utrophin-Dystrophin-
Deficient Mice as a Model for Duchenne Muscular Dystrophy. Cell. 1997; 90(4):717–27. https://doi.org/
10.1016/S0092-8674(00)80532-2. PMID: 9288751
21. Sun Z, Miller RA, Patel RT, Chen J, Dhir R, Wang H, et al. Hepatic Hdac3 promotes gluconeogenesis
by repressing lipid synthesis and sequestration. Nature medicine. 2012; 18(6):934–42. http://www.
nature.com/nm/journal/v18/n6/abs/nm.2744.html#supplementary-information. https://doi.org/10.1038/
nm.2744 PMID: 22561686
22. Bell P, Gao G, Haskins ME, Wang L, Sleeper M, Wang H, et al. Evaluation of Adeno-Associated Viral
Vectors for Liver-Directed Gene Transfer in Dogs. Human Gene Therapy. 2011; 22(8):985–97. https://
doi.org/10.1089/hum.2010.194 PMID: 21204705
23. Kolios G, Valatas V, Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. World
Journal of Gastroenterology: WJG. 2006; 12(46):7413–20. https://doi.org/10.3748/wjg.v12.i46.7413
PubMed PMID: PMC4087584. PMID: 17167827
24. Carpino G, Renzi A, Onori P, Gaudio E. Role of Hepatic Progenitor Cells in Nonalcoholic Fatty Liver Dis-
ease Development: Cellular Cross-Talks and Molecular Networks. International Journal of Molecular
Sciences. 2013; 14(10):20112–30. https://doi.org/10.3390/ijms141020112 PubMed PMID:
PMC3821605. PMID: 24113587
25. Washington K, Wright K, Shyr Y, Hunter EB, Olson S, Raiford DS. Hepatic stellate cell activation in non-
alcoholic steatohepatitis and fatty liver. Human Pathology. 2000; 31(7):822–8. http://dx.doi.org/10.
1053/hupa.2000.8440. PMID: 10923919
26. Magee N, Zou A, Zhang Y. Pathogenesis of Nonalcoholic Steatohepatitis: Interactions between Liver
Parenchymal and Nonparenchymal Cells. BioMed Research International. 2016; 2016:11. https://doi.
org/10.1155/2016/5170402 PMID: 27822476
27. Tacke F, Zimmermann HW. Macrophage heterogeneity in liver injury and fibrosis. Journal of Hepatol-
ogy. 2014; 60(5):1090–6. http://dx.doi.org/10.1016/j.jhep.2013.12.025. PMID: 24412603
28. Luedde T, Schwabe RF. NF-kB in the liver—linking injury, fibrosis and hepatocellular carcinoma. Nat
Rev Gastroenterol Hepatol. 2011; 8(2):108–18. https://doi.org/10.1038/nrgastro.2010.213 PMID:
21293511
29. Pradere J-P, Kluwe J, De Minicis S, Jiao J-J, Gwak G-Y, Dapito DH, et al. Hepatic macrophages but not
dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in
mice. Hepatology. 2013; 58(4):1461–73. https://doi.org/10.1002/hep.26429 PMID: 23553591
30. Xu F, Zhen P, Zheng Y, Lijuan F, Aiting Y, Min C, et al. Preparation of Kupffer cell enriched non-paren-
chymal liver cells with high yield and reduced damage of surface markers by a modified method for flow
cytometry. Cell Biology International. 2013; 37(4):284–91. https://doi.org/10.1002/cbin.10035 PMID:
23348934
31. Xu X, Grijalva A, Skowronski A, van Eijk M, Serlie Mireille J, Ferrante Anthony W Jr. Obesity Activates a
Program of Lysosomal-Dependent Lipid Metabolism in Adipose Tissue Macrophages Independently of
Classic Activation. Cell metabolism. 2013; 18(6):816–30. https://doi.org/10.1016/j.cmet.2013.11.001.
PMID: 24315368
32. Alemany R, Suzuki K, Curiel DT. Blood clearance rates of adenovirus type 5 in mice. Journal of General
Virology. 2000; 81(11):2605–9. https://doi.org/10.1099/0022-1317-81-11-2605 PMID: 11038370
33. Tao N, Gao G-P, Parr M, Johnston J, Baradet T, Wilson JM, et al. Sequestration of Adenoviral Vector
by Kupffer Cells Leads to a Nonlinear Dose Response of Transduction in Liver. Molecular Therapy.
2001; 3(1):28–35. https://doi.org/10.1006/mthe.2000.0227. PMID: 11162308
34. Birmingham A, Anderson EM, Reynolds A, Ilsley-Tyree D, Leake D, Fedorov Y, et al. 3’ UTR seed
matches, but not overall identity, are associated with RNAi off-targets. Nat Meth. 2006; 3(3):199–204.
https://www.nature.com/nmeth/journal/v3/n3/full/nmeth854.html.
35. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biology. 2010;
11(10):R106. https://doi.org/10.1186/gb-2010-11-10-r106 PMID: 20979621
36. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to
Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological). 1995; 57(1):289–
300.
37. Hulsen T, de Vlieg J, Alkema W. BioVenn–a web application for the comparison and visualization of bio-
logical lists using area-proportional Venn diagrams. BMC Genomics. 2008; 9(488). https://doi.org/10.
1186/1471-2164-9-492 PMID: 18928558
38. Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, et al. Genome-Wide Asso-
ciation Analysis Identifies Variants Associated with Nonalcoholic Fatty Liver Disease That Have Distinct
Effects on Metabolic Traits. PLoS genetics. 2011; 7(3):e1001324. https://doi.org/10.1371/journal.pgen.
1001324 PMID: 21423719
ILDR2 has a negligible role in hepatic steatosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0197548 May 30, 2018 17 / 19
39. Dimmock DP, Zhang Q, Dionisi-Vici C, Carrozzo R, Shieh J, Tang LY, et al. Clinical and molecular fea-
tures of mitochondrial DNA depletion due to mutations in deoxyguanosine kinase. Human Mutation.
2008; 29(2):330–1. https://doi.org/10.1002/humu.9519 PMID: 18205204
40. Gao H-Z, Kobayashi K, Tabata A, Tsuge H, Iijima M, Yasuda T, et al. Identification of 16 novel mutations
in the argininosuccinate synthetase gene and genotype–phenotype correlation in 38 classical citrulline-
mia patients. Human Mutation. 2003; 22(1):24–34. https://doi.org/10.1002/humu.10230 PMID:
12815590
41. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, et al. Association analyses
of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010; 42
(11):937–48. http://www.nature.com/ng/journal/v42/n11/abs/ng.686.html#supplementary-information.
https://doi.org/10.1038/ng.686 PMID: 20935630
42. Xie S, Naslavsky N, Caplan S. Diacylglycerol kinases in membrane trafficking. Cellular Logistics. 2015;
5(2):e1078431. https://doi.org/10.1080/21592799.2015.1078431 PMID: 27057419
43. Milne SB, Ivanova PT, Armstrong MD, Myers DS, Lubarda J, Shulga YV, et al. Dramatic Differences in
the Roles in Lipid Metabolism of Two Isoforms of Diacylglycerol Kinase. Biochemistry. 2008; 47
(36):9372–9. https://doi.org/10.1021/bi800492c PMID: 18702510
44. Gorden DL, Ivanova PT, Myers DS, McIntyre JO, VanSaun MN, Wright JK, et al. Increased Diacylgly-
cerols Characterize Hepatic Lipid Changes in Progression of Human Nonalcoholic Fatty Liver Disease;
Comparison to a Murine Model. PLOS ONE. 2011; 6(8):e22775. https://doi.org/10.1371/journal.pone.
0022775 PMID: 21857953
45. De Souza AT, Dai X, Spencer AG, Reppen T, Menzie A, Roesch PL, et al. Transcriptional and pheno-
typic comparisons of Ppara knockout and siRNA knockdown mice. Nucleic Acids Research. 2006; 34
(16):4486–94. https://doi.org/10.1093/nar/gkl609 PMID: 16945951
46. Iacobas DA, Iacobas S, Urban-Maldonado M, Scemes E, Spray DC. Similar Transcriptomic Alterations
in Cx43 Knockdown and Knockout Astrocytes. Cell Communication & Adhesion. 2008; 15(1–2):195–
206. https://doi.org/10.1080/15419060802014222 PMID: 18649190
47. Kok Fatma O, Shin M, Ni C-W, Gupta A, Grosse Ann S, van Impel A, et al. Reverse Genetic Screening
Reveals Poor Correlation between Morpholino-Induced and Mutant Phenotypes in Zebrafish. Develop-
mental cell. 2015; 32(1):97–108. https://doi.org/10.1016/j.devcel.2014.11.018. PMID: 25533206
48. Daude N, Wohlgemuth S, Brown R, Pitstick R, Gapeshina H, Yang J, et al. Knockout of the prion protein
(PrP)-like Sprn gene does not produce embryonic lethality in combination with PrPC-deficiency. Pro-
ceedings of the National Academy of Sciences. 2012; 109(23):9035–40. https://doi.org/10.1073/pnas.
1202130109 PMID: 22619325
49. Smart N, Riley PR. Thymosin β4 in Vascular Development Response to Research Commentary. Circu-
lation Research. 2013; 112(3):e29–e30. https://doi.org/10.1161/CIRCRESAHA.112.300555 PMID:
23371906
50. Gao Y, Zhang Y, Zhang D, Dai X, Estelle M, Zhao Y. Auxin binding protein 1 (ABP1) is not required for
either auxin signaling or Arabidopsis development. Proceedings of the National Academy of Sciences.
2015; 112(7):2275–80. https://doi.org/10.1073/pnas.1500365112 PMID: 25646447
51. Mannerås-Holm L, Kirchner H, Bjo¨rnholm M, Chibalin AV, Zierath JR. mRNA expression of diacylgly-
cerol kinase isoforms in insulin-sensitive tissues: effects of obesity and insulin resistance. Physiological
Reports. 2015; 3(4). https://doi.org/10.14814/phy2.12372 PMID: 25847921
52. Ugai H, Watanabe S, Suzuki E, Tsutsui-Nakata H, Yokoyama KK, Murata T. Stability of a Recombinant
Adenoviral Vector: Optimization of Conditions for Storage, Transport and Delivery. Japanese Journal of
Cancer Research. 2002; 93(5):598–603. https://doi.org/10.1111/j.1349-7006.2002.tb01296.x PMID:
12036457
53. Krajden M, Minor JM, Rifkin O, Comanor L. Effect of Multiple Freeze-Thaw Cycles on Hepatitis B Virus
DNA and Hepatitis C Virus RNA Quantification as Measured with Branched-DNA Technology. Journal
of Clinical Microbiology. 1999; 37(6):1683–6. PMID: 10325307
54. Furuse M, Izumi Y, Oda Y, Higashi T, Iwamoto N. Molecular organization of tricellular tight junctions.
Tissue Barriers. 2014; 2(3):e28960. https://doi.org/10.4161/tisb.28960 PMID: 25097825
55. Higashi T, Tokuda S, Kitajiri S-i, Masuda S, Nakamura H, Oda Y, et al. Analysis of the ‘angulin’ proteins
LSR, ILDR1 and ILDR2 –tricellulin recruitment, epithelial barrier function and implication in deafness
pathogenesis. Journal of Cell Science. 2013; 126(4):966–77. https://doi.org/10.1242/jcs.116442 PMID:
23239027
56. Halldorsdottir S, Carmody J, Boozer CN, Leduc CA, Leibel RL. Reproducibility and accuracy of body
composition assessments in mice by dual energy x-ray absorptiometry and time domain nuclear mag-
netic resonance. International journal of body composition research. 2009; 7(4):147–54. PubMed
PMID: PMC3169293. PMID: 21909234
ILDR2 has a negligible role in hepatic steatosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0197548 May 30, 2018 18 / 19
57. Folch J, Lees M, Stanley GHS. A simple method for the isolation and purification of total lipides from ani-
mal tissues. The Journal of biological chemistry. 1956; 226:497.
58. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet.
2009; 10(1):57–63. https://doi.org/10.1038/nrg2484 PMID: 19015660
59. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics.
2009; 25(9):1105–11. https://doi.org/10.1093/bioinformatics/btp120 PMID: 19289445
ILDR2 has a negligible role in hepatic steatosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0197548 May 30, 2018 19 / 19
